Piperidines
Medchemexpress LLC HY-B0563B 10mg Medchemexpress, Ropivacaine hydrochloride CAS:98717-15-8 Purity:>98%
Medchemexpress, HY-B0563B 10mg Ropivacaine hydrochloride CAS:98717-15-8 Ropivacaine hydrochloride is an inhibitor of K 2P (two-pore domain potassium channel) TREK-1 with an IC 50 of 402.7 μM. Purity:>98% Medchemexpress has over 10000 novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. Other quantity can also be offered.
Apexbio Technology LLC Ropivacaine hydrochloride monohydrate 132112-35-7 10mM (in 1mL DMSO)
Ropivacaine hydrochloride monohydrate (CAS 132112-35-7) is a long-acting amide local anesthetic widely studied for its pharmacological and electrophysiological properties It inhibits ATP-sensitive potassium (KATP) channels particularly SUR2A/Kir6 2 as demonstrated in COS-7 cell models where inhibition is concentration-dependent and reversible Reported IC50 values for SUR2A/Kir6 2 SUR2B/Kir6 1 SUR2B/Kir6 2 and Kir6 2 C36 channels are 249 11 2235 115 2442 132 and 2375 179 M respectively Additionally ropivacaine hydrochloride monohydrate suppresses sarcolemmal KATP channels in cardiovascular tissues via stereoselective and tissue-specific mechanisms supporting its utility in studies of ion channel pharmacology and cardiovascular safety profiles
Apexbio Technology LLC Ropivacaine hydrochloride monohydrate 132112-35-7 50mg
Ropivacaine hydrochloride monohydrate (CAS 132112-35-7) is a long-acting amide local anesthetic widely studied for its pharmacological and electrophysiological properties It inhibits ATP-sensitive potassium (KATP) channels particularly SUR2A/Kir6 2 as demonstrated in COS-7 cell models where inhibition is concentration-dependent and reversible Reported IC50 values for SUR2A/Kir6 2 SUR2B/Kir6 1 SUR2B/Kir6 2 and Kir6 2 C36 channels are 249 11 2235 115 2442 132 and 2375 179 M respectively Additionally ropivacaine hydrochloride monohydrate suppresses sarcolemmal KATP channels in cardiovascular tissues via stereoselective and tissue-specific mechanisms supporting its utility in studies of ion channel pharmacology and cardiovascular safety profiles
Apexbio Technology LLC Vanoxerine dihydrochloride 67469-78-7 10mg
Vanoxerine dihydrochloride is a small-molecule inhibitor targeting the dopamine transporter (DAT1) human ether- -go-go-related gene (hERG Kv11 1) potassium channel cardiac sodium channel (hNaV1 5) and L-type calcium channels (ICa L) It modulates neurotransmitter uptake and cardiac ion channel conductance thereby regulating synaptic dopamine levels and cardiac electrophysiology Vanoxerine dihydrochloride exerts its biological activity primarily through inhibition of dopamine reuptake and blockade of multiple cardiac ion channels It demonstrates antagonist activity at DAT1 (Ki 16 9 nM) potent inhibition of hERG channels (IC50 0 84 nM) and inhibitory effects on hNaV1 5 (IC50 830 nM) and ICa L (IC50 320 nM) Based on these pharmacological properties vanoxerine dihydrochloride holds research potential in cardiac arrhythmia studies
Apexbio Technology LLC Vanoxerine dihydrochloride 67469-78-7 50mg
Vanoxerine dihydrochloride is a small-molecule inhibitor targeting the dopamine transporter (DAT1) human ether- -go-go-related gene (hERG Kv11 1) potassium channel cardiac sodium channel (hNaV1 5) and L-type calcium channels (ICa L) It modulates neurotransmitter uptake and cardiac ion channel conductance thereby regulating synaptic dopamine levels and cardiac electrophysiology Vanoxerine dihydrochloride exerts its biological activity primarily through inhibition of dopamine reuptake and blockade of multiple cardiac ion channels It demonstrates antagonist activity at DAT1 (Ki 16 9 nM) potent inhibition of hERG channels (IC50 0 84 nM) and inhibitory effects on hNaV1 5 (IC50 830 nM) and ICa L (IC50 320 nM) Based on these pharmacological properties vanoxerine dihydrochloride holds research potential in cardiac arrhythmia studies
Apexbio Technology LLC Vanoxerine dihydrochloride 67469-78-7 25mg
Vanoxerine dihydrochloride is a small-molecule inhibitor targeting the dopamine transporter (DAT1) human ether- -go-go-related gene (hERG Kv11 1) potassium channel cardiac sodium channel (hNaV1 5) and L-type calcium channels (ICa L) It modulates neurotransmitter uptake and cardiac ion channel conductance thereby regulating synaptic dopamine levels and cardiac electrophysiology Vanoxerine dihydrochloride exerts its biological activity primarily through inhibition of dopamine reuptake and blockade of multiple cardiac ion channels It demonstrates antagonist activity at DAT1 (Ki 16 9 nM) potent inhibition of hERG channels (IC50 0 84 nM) and inhibitory effects on hNaV1 5 (IC50 830 nM) and ICa L (IC50 320 nM) Based on these pharmacological properties vanoxerine dihydrochloride holds research potential in cardiac arrhythmia studies